References and Recommended Reading
Of major importance Marin RS, Wilkosz PA:Disorders of diminished motivation.J Head Trauma Rehab 2005,20:377–388. Excellent theoretical discussion and review of the literature pertaining to the neurobiology, assessment, and treatment of apathy and other “disorders of motivation” such as abulia.
McAllister TW:Apathy.Semin Clin Neuropsychiatry 2000,5:275–282.
Stuss DT, van Reekum RJMK:Differentiation of states and causes of apathy. InThe Neuropsychology of Emotion. Edited by Bor JC. New York: Oxford University Press; 2000:340–363.
Levy R, Dubois B:Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits.Cereb Cortex 2006,16:916–928.
Marin RS, Biedrzycki RC, Firinciogullari S:Reliability and validity of the Apathy Evaluation Scale.Psychiatry Res 1991,38:143–162.
Starkstein SE, Petracca G, Chemerinski E, et al.:Syndromic validity of apathy in Alzheimer’s disease.Am J Psychiatry 2001,158:872–877.
Cummings JL, Mega M, Gray K, et al.:The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.Neurology 1994,44:2308–2314.
Andreasen NC:Scale for the Assessment of Negative Symptoms (SANS). Iowa City: College of Medicine, University of Iowa; 1984.
Kirsch-Darrow L, Fernandez HF, Marsiske M, et al.:Dissociating apathy and depression in Parkinson disease.Neurology 2006,67:33–38.
Kiang M, Christensen BK, Remington G, et al.:Apathy in schizophrenia: clinical correlates and association with functional outcome.Schizophr Res 2003,63:79–88.
van Reekum R, Stuss DT, Ostrander L:Apathy: why care? J Neuropsychiatry Clin Neurosci 2005,17:7–19.
Paul RH, Brickman AM, Navia B, et al.:Apathy is associated with volume of the nucleus accumbens in patients infected with HIV.J Neuropsychiatry Clin Neurosci 2005,17:167–171.
Roth RM, Flashman LA, Saykin AJ, et al.:Apathy in schizophrenia: reduced frontal lobe volume and neuropsychological deficits.Am J Psychiatry 2004,161:157–159.
Rosen HJ, Allison SC, Schauer GF, et al.:Neuroanatomical correlates of behavioural disorders in dementia.Brain 2005,128:2612–2625.
Baudic S, Maison P, Dolbeau G, et al.:Cognitive impairment related to apathy in early Huntington’s disease.Dement Geriatr Cogn Disord 2006,21:316–321.
McPherson S, Fairbanks L, Tiken S, et al.:Apathy and executive function in Alzheimer’s disease.J Int Neuropsychol Soc 2002,8:373–381.
Barnhart WJ, Makela EH, Latocha MJ:SSRI-induced apathy syndrome: a clinical review.J Psychiatr Pract 2004,10:196–199.
Chatterjee A, Fahn S:Methylphenidate treats apathy in Parkinson’s disease.J Neuropsychiatry Clin Neurosci 2002,14:461–462.
Keenan S, Mavaddat N, Iddon J, et al.:Effects of methylphenidate on cognition and apathy in normal pressure hydrocephalus: a case study and review.Br J Neurosurg 2005,19:46–50.
Jansen IH, Olde Rikkert MG, Hulsbos HA, et al.:Toward individualized evidence-based medicine: five “N of 1” trials of methylphenidate in geriatric patients.J Am Geriatr Soc 2001,49:474–476.
Padala PR, Petty F, Bhatia SC:Methylphenidate may treat apathy independent of depression.Ann Pharmacother 2005,39:1947–1949.
Padala PR, Burke WJ, Bhatia SC, et al.:Treatment of apathy with methylphenidate.J Neuropsychiatry Clin Neurosci 2007,19:81–83.
Van Reekum R, Bayley M, Garner S, et al.:N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury.Brain Inj 1995,9:49–53.
Kraus MF, Maki PM:Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review.J Neuropsychiatry Clin Neurosci 1997,9:222–230.
Marin RS, Fogel BS, Hawkins J, et al.:Apathy: a treatable syndrome.J Neuropsychiatry Clin Neurosci 1995,7:23–30.
Debette S, Kozlowski O, Steinling M, et al.:Levodopa and bromocriptine in hypoxic brain injury.J Neurol 2002,249:1678–1682.
Czernecki V, Pillon B, Houeto JL, et al.:Motivation, reward, and Parkinson’s disease: influence of dopatherapy.Neuropsychologia 2002,40:2257–2267.
Newburn G, Newburn D:Selegiline in the management of apathy following traumatic brain injury.Brain Inj 2005,19:149–154
Corcoran C, Wong ML, O’Keane V:Bupropion in the management of apathy.J Psychopharmacol 2004,18:133–135.
Gauthier S, Feldman H, Hecker J, et al.:Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease.Int Psychogeriatr 2002,14:389–404.
Masanic CA, Bayley MT, VanReekum R, et al.:Open-label study of donepezil in traumatic brain injury.Arch Phys Med Rehabil 2001,7:896–901.
Brodaty H, Woodward M, Boundy K, et al.:A naturalistic study of galantamine for Alzheimer’s disease.CNS Drugs 2006,20:935–943.
Arnold DS, Rosse RB, Dickinson D, et al.:Adjuvant therapeutic effects of galantamine on apathy in a schizophrenia patient.J Clin Psychiatry 2004,65:1723–1724.
Edwards KR, Hershey L, Wray L, et al.:Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis.Dement Geriatr Cogn Disord 2004,17(Suppl 1):40–48.
Cummings JL, Koumaras B, Chen M, et al.:Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer’s disease: a 26-week, multicenter, open-label study.Am J Geriatr Pharmacother 2005,3:137–148.
McKeith IG, Grace JB, Walker Z, et al.:Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial.Int J Geriatr Psychiatry 2000,15:387–392.
Alvarez E, Ciudad A, Olivares JM, et al.:A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.J Clin Psychopharmacol 2006,26:238–249.
Marangell LB, Johnson CR, Kertz B, et al.:Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study J Clin Psychiatry 2002,63:391–395.
Negrón AE, Reichman WE:Risperidone in the treatment of patients with Alzheimer’s disease with negative symptoms.Int Psychogeriatr 2000,12:527–536.
Politis AM, Vozzella S, Mayer LS, et al.:A randomized, controlled, clinical trial of activity therapy for apathy in patients with dementia residing in long-term care.Int J Geriatr Psychiatry 2004,19:1087–1094.
Of importance Chapman SB, Weiner MF, Rackley A, et al.:Effects of cognitive-communication stimulation for Alzheimer’s disease patients treated with donepezil J Speech Lang Hear Res 2004,47:1149–1163. This randomized trial of patients with Alzheimer’s disease showed that combining donepezil with a psychologic intervention, in this case cognitive-communication therapy, yields a greater improvement of apathy than does donepezil alone.
Verkaik R, van Weert JC, Francke AL:The effects of psychosocial methods on depressed, aggressive and apathetic behaviors of people with dementia: a systematic review.Int J Geriatr Psychiatry 2005,20:301–314.
Finnema E, Droes RM, Ettema T, et al.:The effect of integrated emotion-oriented care versus usual care on elderly persons with dementia in the nursing home and on nursing assistants: a randomized clinical trial Int J Geriatr Psychiatry 2005,20:330–343.
Kragt K, Holtkamp CCM, Dongen MCJM, et al.:[The effect of snoezelen in the sensory stimulation room on the well-being of demented elderly. A cross-over trial in resisdents of the R.C. Care Center Bernardus in Amsterdam].Verpleegkunde 1997,12:227–236.
Hopman-Rock M, Staats PGM, Tak ECPM, et al.:The effects of a psychomotor activation program for use in groups of cognitively impaired people in homes for the elderly Int J Geriatr Psychiatry 1999,14:633–642.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Roth, R.M., Flashman, L.A. & McAllister, T.W. Apathy and its treatment. Curr Treat Options Neurol 9, 363–370 (2007). https://doi.org/10.1007/BF02938543
Issue Date:
DOI: https://doi.org/10.1007/BF02938543